Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
Gideon M. Hirschfield(University Health Network), DE Jones, John M. Vierling(Baylor College of Medicine), Sandrin C. Bergheanu, Christopher L. Bowlus(University of California, Davis), Richard Aspinall(Queen Alexandra Hospital), Charles A. McWherter(University Health Network), Stuart C. Gordon(United States Department of Veterans Affairs), Christelle Lévy(Centre François Baclesse), Roland Martinꝉ(University of Zurich), M.J. Mayo, Pol Boudes(CymaBay Therapeutics (United States)), Daniel Bernstein(Stanford University), Paul J. Thuluvath(University of Maryland, Baltimore), A. Steinberg, D. Sheridan, Lynsey Corless(University of Hull), G. Michael, Peter Buggisch(Institute for Interdisciplinary Medicine), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mark G. Swain(University of Calgary), Joseph A. Odin(University of Pittsburgh), MA Wörns, Mónika Varga(CymaBay Therapeutics (United States)), Yu-Seong Choi, Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), C Berg, T. Hassanein, Yvonne Döerffel(Charité - Universitätsmedizin Berlin), M. Shiffman, S. Harrison, Douglas Thorburn(Royal Free London NHS Foundation Trust), B. Bacon, Norman Gitlin(NYU Langone Health)
Cited by 5
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k